Roivant director plans sale of 22,688 shares

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) director Melissa Epperly has filed a Form 144 indicating an intent to sell up to 22,688 shares of common stock through Morgan Stanley Smith Barney LLC, with an estimated aggregate market value of $930,661.76 as of September 15, 2026. The planned sales include shares to be received from the exercise of stock options for 17,750 shares dated September 15, 2026 and from restricted stock units for 4,938 shares dated September 10, 2026. The notice states the securities to be sold will be received upon option exercises over the next three months, and that the dates of acquisition and payment will be the dates of exercise or sale. Epperly previously sold 17,750 shares of Roivant common stock on June 29, 2026 for $610,188.20 under a 10b5-1 trading plan.

Key Figures

Shares proposed for sale: 22,688 shares Estimated aggregate market value: $930,661.76 Stock options-related shares: 17,750 shares +3 more

6 metrics

Shares proposed for sale 22,688 shares Common stock covered by the Form 144 as of September 15, 2026

Estimated aggregate market value $930,661.76 Value of 22,688 shares of common stock related to the proposed sales

Stock options-related shares 17,750 shares Shares to be received from exercise of stock options dated September 15, 2026

Restricted stock unit shares 4,938 shares Shares from restricted stock units dated September 10, 2026

Recent 10b5-1 sale 17,750 shares for $610,188.20 Sale of common stock on June 29, 2026 under a 10b5-1 plan

Date of Form 144 notice September 15, 2026 Date the notice of proposed sale of securities was filed

Key Terms

Rule 144, 10b5-1, Restricted Stock Units, Exercise of Stock Options

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for MELISSA B EPPERLY 7th Floor 50 Broadway"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Restricted Stock Units financial

"Common | 09/10/2026 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Exercise of Stock Options financial

"Common | 09/15/2026 | Exercise of Stock Options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Roivant Sciences (ROIV)?

The filing discloses that director Melissa Epperly plans potential sales of up to 22,688 shares of Roivant Sciences common stock, with an estimated aggregate market value of $930,661.76, through Morgan Stanley Smith Barney LLC as of September 15, 2026.

How many Roivant (ROIV) shares are linked to stock options and RSUs in this Form 144?

The notice lists 17,750 shares to be received upon the exercise of stock options dated September 15, 2026 and 4,938 shares from restricted stock units dated September 10, 2026, together corresponding to the 22,688 shares covered by the Form 144.

What prior Roivant (ROIV) sales by Melissa Epperly are reported in the last three months?

The filing reports that on June 29, 2026, Melissa Epperly sold 17,750 shares of Roivant common stock for total proceeds of $610,188.20 under a 10b5-1 trading plan.

What trading plan is referenced in the Roivant (ROIV) Form 144?

Sales during the past three months are described as 10b5-1 sales for Melissa B. Epperly, including the June 29, 2026 sale of 17,750 shares for $610,188.20 of Roivant Sciences common stock.

Over what period does the Roivant (ROIV) Form 144 expect option-related sales?

The remarks state that the securities to be sold will be received upon the exercise of stock options over the next three months, and that the dates of acquisition and payment will be the dates of exercise or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 04:41 PM Accepted by SEC EDGAR 09/15/2026 - 04:40 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001807359
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ROIVANT SCIENCES LTD
SEC File Number	001-40782
Address of Issuer	7th Floor 50 Broadway London UNITED KINGDOM SW1H 0DB
Phone	442074003347
Name of Person for Whose Account the Securities are To Be Sold	MELISSA EPPERLY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	22688	930661.76	722323015	09/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2026	Exercise of Stock Options	Issuer			17750	09/15/2026	Cash
Common	09/10/2026	Restricted Stock Units	Issuer			4938	09/10/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for MELISSA B EPPERLY 7th Floor 50 Broadway London X0 SW1H 0DB	Common	06/29/2026	17750	610188.20

144: Remarks and Signature

Remarks	The securities to be sold will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment will be the dates of exercise/sale.
Date of Notice	09/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/30/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Melissa Epperly
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)